Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Tinzaparin sodium
Drug ID BADD_D02222
Description Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally. LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Indications and Usage Tinzaparin is used for the prevention of postoperative venous thromboembolism in patients undergoing orthopedic surgery and in patients undergoing general surgery who are at high risk of developing postoperative venous thromboembolism. It is also used for the treatment of deep vein thrombosis and/or pulmonary embolism. It is indicated for use in preventing clot formation in indwelling intravenous lines for hemodialysis.
Marketing Status approved
ATC Code B01AB10
DrugBank ID DB06822
KEGG ID D06398
MeSH ID D000078222
PubChem ID 8784
TTD Drug ID D01ZJK
NDC Product Code Not Available
UNII 3S182ET3UA
Synonyms Tinzaparin | 2-Propenoic acid, 3-phenyl- | 2 Propenoic acid, 3 phenyl | 3-phenyl- 2-Propenoic acid | Tinzaparin Sodium | Innohep
Chemical Information
Molecular Formula C9H8O2
CAS Registry Number 621-82-9
SMILES C1=CC=C(C=C1)C=CC(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haematoma24.07.01.001--
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
Haemoptysis02.11.04.009; 24.07.01.006; 22.02.03.004--Not Available
Haemorrhage intracranial24.07.04.003; 17.08.01.008--
Headache17.14.01.001--
Henoch-Schonlein purpura23.06.01.002; 10.02.02.004; 01.01.04.001; 24.07.06.003--Not Available
Hepatitis cholestatic09.01.01.002--Not Available
Hypersensitivity10.01.03.003--
Hypotonia17.05.02.002; 15.05.04.008--Not Available
Impaired healing08.03.02.001--Not Available
Infection11.01.08.002--Not Available
Injection site haemorrhage24.07.01.010; 12.07.03.005; 08.02.03.005--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Melaena24.07.02.013; 07.12.02.004--Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.001--
Necrosis24.04.02.006; 08.03.03.001--Not Available
Neoplasm16.16.02.001--Not Available
Osteochondrosis15.07.03.002--Not Available
Pain08.01.08.004--
Pancytopenia01.03.03.003--Not Available
Pericardial haemorrhage24.07.01.013; 02.06.01.003--Not Available
Peripheral ischaemia24.04.03.002--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Priapism24.04.12.007; 21.03.01.005--Not Available
Pruritus23.03.12.001--
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages